Respiratory Rehabilitation Based on Eccentric Exercice on Treadmill After Thoracic Surgery
Launched by UNIVERSIDAD EUROPEA DE MADRID · Jul 2, 2024
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special exercise program designed to help patients who have recently undergone thoracic surgery, which includes surgeries on the lungs or chest area. The focus is on using a type of exercise called eccentric training, which involves lengthening muscles while they are under tension. The goal is to see if this type of training can improve strength, lung capacity, and overall health in patients who experience difficulty breathing, known as dyspnea, after surgery.
To participate, individuals must be over 18 years old, have had thoracic surgery within the last 75 days, and experience moderate difficulty in breathing. Participants will take part in 12 group exercise sessions over four weeks, with each session lasting about 75 minutes. The exercises will include both strength training and breathing exercises. Participants will also take tests to measure their progress before, immediately after, and one month after completing the program. It's important to note that certain medical conditions could prevent someone from joining, such as severe heart issues or recent cardiovascular events. This trial offers a chance to improve recovery and quality of life after surgery through targeted exercise.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects \>18 years.
- • Thoracic surgery in the previous 75 days
- • Present dyspnea grade 2 - 3 on the mMRC scale.
- • Cognitive and functional level sufficient to understand, learn and carry out the exercise program.
- • Not have contraindications to perform physical training.
- • Active collaborators.
- Exclusion Criteria:
- • Severe intolerance to exertion due to untreated cardiac arrhythmias, ischemia during low intensity exercise (anginas unstable), severe pulmonary hypertension, heart failure (NYHA III or IV)
- • Pulmonary embolism with anticoagulant treatment less than 5 days.
- • Recent cardiovascular events such as congestive heart failure, angioplasties or cardiac surgeries of less than four weeks' duration, valvular alterations requiring surgical correction, myopericarditis, ventricular arrhythmias caused by exercise.
- • Kidney failure requiring dialysis.
- • Patients with uncontrolled bronchospasm due to intrinsic asthma.
- • Patients undergoing post-surgery chemotherapy treatment.
- • Adverse effects that occurred during the development of the treatment.
About Universidad Europea De Madrid
Universidad Europea de Madrid (UEM) is a leading academic institution dedicated to advancing research and education in various fields, including health sciences. As a clinical trial sponsor, UEM is committed to fostering innovative research that contributes to the understanding and improvement of medical practices. The university collaborates with healthcare professionals and researchers to design and implement rigorous clinical trials, ensuring adherence to ethical standards and regulatory guidelines. UEM's focus on interdisciplinary collaboration and cutting-edge research methodologies positions it as a pivotal player in the advancement of clinical knowledge and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, Spain
Patients applied
Trial Officials
Teresa Fernandez Pardo, Msc
Study Director
Universidad Europea de Madrid
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported